Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HUMA Humacyte Inc
- Stocks
- Healthcare
- NASDAQ: HUMA
Price (delayed)
$2.24
Market cap
$347.47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.69
Enterprise value
$316.62M
Highlights
The company's equity has surged by 168% QoQ and by 38% YoY
HUMA's net income is up by 48% since the previous quarter and by 27% year-on-year
The quick ratio is down by 31% YoY but it is up by 19% QoQ
HUMA's debt is up by 7% year-on-year
Key stats
What are the main financial stats of HUMA
Market
Valuations
Earnings
Shares outstanding
155.12M
Market cap
$347.47M
Enterprise value
$316.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.64
Price to sales (P/S)
569.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
612.42
Revenue
$517,000
Gross profit
$370,000
Operating income
-$111M
Net income
-$77.67M
EBIT
-$67.21M
EBITDA
-$59.92M
Free cash flow
-$100.79M
Per share
Balance sheet
Liquidity
EPS
-$0.69
EPS diluted
-$0.69
Free cash flow per share
-$0.77
Book value per share
$0.23
Revenue per share
$0
TBVPS
$1.24
Total assets
$162.55M
Total liabilities
$126.51M
Debt
$82.21M
Equity
$36.04M
Working capital
$53.68M
Debt to equity
2.28
Current ratio
3.68
Quick ratio
5.67
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-11,589.9%
Gross margin
71.6%
Net margin
-15,022.4%
Operating margin
-21,470.8%
Return on assets
-56.1%
Return on equity
N/A
Return on invested capital
-63.6%
Return on capital employed
-47.2%
Return on sales
-12,999%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HUMA stock price
How has the Humacyte stock price performed over time
Intraday
18.52%
1 week
88.24%
1 month
44.52%
1 year
-65.11%
YTD
-55.64%
QTD
31.38%
Financial performance
How have Humacyte's revenue and profit performed over time
Revenue
$517,000
Gross profit
$370,000
Operating income
-$111M
Net income
-$77.67M
Gross margin
71.6%
Net margin
-15,022.4%
HUMA's net income is up by 48% since the previous quarter and by 27% year-on-year
HUMA's operating income is down by 7% year-on-year but it is up by 3% since the previous quarter
Price vs fundamentals
How does HUMA's price correlate with its fundamentals
Growth
What is Humacyte's growth rate over time
Valuation
What is Humacyte stock price valuation
P/E
N/A
P/B
9.64
P/S
569.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
612.42
HUMA's EPS is up by 45% since the previous quarter and by 31% year-on-year
The company's equity has surged by 168% QoQ and by 38% YoY
Efficiency
How efficient is Humacyte business performance
HUMA's return on invested capital has surged by 52% since the previous quarter and by 38% year-on-year
Humacyte's return on assets has increased by 48% QoQ and by 19% YoY
Dividends
What is HUMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HUMA.
Financial health
How did Humacyte financials performed over time
HUMA's total assets is 28% higher than its total liabilities
HUMA's current ratio has plunged by 56% YoY but it has soared by 53% from the previous quarter
Humacyte's total liabilities has decreased by 34% QoQ and by 7% YoY
HUMA's debt is 128% greater than its equity
The company's equity has surged by 168% QoQ and by 38% YoY
The debt to equity has declined by 22% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.